# Is PT-141 FDA-Approved? Regulatory Status of the PT-141 Peptide > Is PT-141 fda-approved? Yes — as bremelanotide (NDA 210557, 2019) for premenopausal HSDD in women only. Everything else is off-label or research-grade. The PT-141 regulatory record, cited. The short answer is yes — for one narrow use. The longer answer is the line between the approved drug and the research-grade peptide. ## The short version Is PT-141 fda-approved? Yes — but read the fine print, because it is the whole story. PT-141 is the lab name for bremelanotide, which the FDA approved on June 21, 2019 (application number NDA 210557) [7]. The approval is for one use only: low sexual desire that causes distress (HSDD) in women who have not yet reached menopause [7]. That is the entire approved use. It is not approved for men. It is not approved for postmenopausal women. It is not approved to enhance "performance" or for weight or appetite. Those uses range from investigational to unstudied — we label each one off-label or research-grade where it appears. There is a second layer. The approved drug is a regulated, prescription pharmaceutical. The "PT-141" sold as a research chemical is a different thing legally: it sits outside the approval framework, with no oversight of what is actually in the vial. Same lab name, very different regulatory standing. ## What the approval actually covers Bremelanotide was approved for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women [7]. "Acquired" means the low desire developed after a period of normal function; "generalized" means it is not limited to one partner or situation. The approval is narrow by design — it tracks exactly the population studied in the pivotal trials. The label specifies the form: a 1.75 mg subcutaneous injection, taken as needed, with a ceiling of one dose per 24 hours and no more than eight doses per month [7]. It carries a warning about transient increases in blood pressure and contraindicates use in uncontrolled hypertension or known cardiovascular disease [7]. The numbers and the cautions are label-attested — they come from the FDA-approved prescribing information, which is the authoritative source for the approved drug. ## How the approval came together The approval rested on two identical Phase 3 randomized controlled trials, known as the RECONNECT program (studies 301 and 302), enrolling 1,267 premenopausal women with HSDD [3]. Both trials met their coprimary endpoints: a statistically significant improvement in sexual desire (FSFI-desire) and a reduction in desire-related distress (FSDS-DAO) over 24 weeks [3]. A 52-week open-label extension then followed 684 women and found sustained benefit with no new safety signals [4]. Before that, the development history ran through other routes and other indications: an intranasal program for erectile dysfunction with a completed Phase IIb trial [10], and Phase II human trials in erectile dysfunction characterized in the melanocortin literature [12]. Those did not lead to approval. The subcutaneous HSDD program in premenopausal women did. ## Where the approval has been questioned Approval is not the same as unanimous endorsement, and the regulatory record includes credible criticism worth surfacing. A 2021 analysis argued that the desire and distress effects, while statistically significant, are small, that on average the trials did not show additional satisfying sexual events, and that the approval leaned on the regulatory precedent set by an earlier drug for the same condition [9]. A 2018 review of HSDD management placed bremelanotide in late-stage development at the time and recommended a broader biopsychosocial approach to low desire rather than a drug-first one [8]. None of this undoes the approval. It does mean the honest summary is: approved, on real Phase 3 evidence, for a real but modest benefit, with a notable tolerability cost — not a blockbuster effect. That nuance is the point of reading the record rather than a headline. ## Legal status and the research-chemical question Within the United States, the approved drug is a lawful prescription medicine for its approved indication [7]. Material sold as "PT-141 research chemical" is a separate matter: it is sold for laboratory research use, is not for human consumption, and is not subject to the identity, purity, and concentration controls that apply to an approved pharmaceutical. Buying a research-grade peptide is not the same as receiving the approved drug, even though the lab name is identical. On the anti-doping side, melanocortin receptor agonists fall under WADA's framework for non-approved substances in contexts without current therapeutic approval; athletes should consult current WADA guidance directly. This page summarizes the published regulatory record and the approved label; it is not legal or medical advice. --- A clinical reading room for the PT-141 (bremelanotide) record, read under one desk lamp — the single approved use logged in crimson before anything else, the label figures kept apart from the study findings and both apart from the unverified reports, with no clinic behind the door and nothing here dosed, sourced, or sold.